Mesoblast Limited has achieved a significant milestone in its development of a treatment for chronic low back pain, announcing that it has treated its target of 300 patients in the pivotal Phase 3 MSB-DR004 trial for rexlemestrocel-L. This enrollment target completion represents a critical inflection point for the biotech company, signaling that its confirmatory trial is now adequately powered to demonstrate whether the product can meet its primary endpoint of reducing pain at 12 months compared to sham controls.
The trial builds on positive results from an earlier Phase 3 study, MSB-DR003, which successfully met its pain reduction endpoint and demonstrated meaningful opioid cessation rates among treated patients. The focus on opioid reduction carries particular weight given that discogenic back pain accounts for approximately 50 percent of prescription opioid usage in the United States. For investors, this suggests a therapeutic application addressing both a medical need and a public health priority, potentially improving the regulatory pathway and reimbursement outlook.
Chronic low back pain associated with degenerative disc disease affects more than 7 million people in the U.S. alone, and Mesoblast has indicated the indication could be a blockbuster product with potential peak year revenues exceeding US$10 billion at single digit market penetration. That scale of opportunity reflects the significant unmet need in a market where conservative treatment often fails and surgical options carry their own risks and recovery challenges. The company is proceeding with commercial manufacturing in parallel with trial execution, positioning itself to file for regulatory approval as soon as results are available.
From a regulatory standpoint, rexlemestrocel-L carries FDA Regenerative Medicine Advanced Therapy (RMAT) designation, which provides priority review and rolling review eligibility once a Biologics License Application is filed. These designations typically accelerate the path to approval and reflect FDA confidence in the product’s potential to address unmet medical needs. The company expects to report top-line results in mid-2027 after the last treated patient completes the mandated 12-month follow-up period.
Looking ahead, investors should monitor whether secondary endpoints for quality of life and opioid cessation prove as compelling as the primary pain reduction measure, as these factors could significantly influence commercial potential and reimbursement decisions. Mesoblast’s achievement of its enrollment target removes a near-term operational risk and advances the company toward a potential value-inflecting catalyst in mid-2027 when top-line results are expected. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Mesoblast Limited (ASX: MSB)
Mesoblast Limited is a biotechnology company headquartered in Melbourne, Australia, specializing in the development of allogeneic cellular medicines derived from adult stem cells. The company focuses on treating severe and life-threatening inflammatory conditions, with a pipeline spanning cardiovascular diseases, spine orthopedic disorders, and immune-mediated conditions. It is a world leader in the development of off-the-shelf cellular medicine therapies for these therapeutic areas.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
